Description
50 Studies Every Psychiatrist Should Know presents key studies that have shaped the practice of psychiatry. Selected using a rigorous methodology, the studies cover topics including: psychotic disorders, depressive disorders, women's mental health, child and adolescent disorders, and epidemiological studies. For each study, a concise summary is presented with an emphasis on the results and limitations of the study, and its implications for practice. An illustrative clinical case concludes each review, followed by brief information on other relevant studies. This book is a must-read for health care professionals and anyone who wants to learn more about the data behind clinical practice.
Table of Contents
Section 1: Anxiety DisordersChapter 1: Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic DisorderAmanda Sun and Tobias WasserChapter 2: Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placebo in Generalized Social PhobiaErin Habecker and Tobias WasserSection 2: Bipolar DisorderChapter 3: Lithium Plus Valproate Combination Versus Monotherapy for Relapse Prevention in Bipolar I Disorder (BALANCE)João Paulo De Aquino and Robert BeechChapter 4: Mood Stabilizer Monotherapy vs. Adjunctive Antidepressant for Bipolar Depression: The STEP-BD TrialJoão Paulo De Aquino and Robert BeechChapter 5: Suicide Risk in Bipolar Disorder: Comparing Lithium, Divalproex, and CarbamazepineRachel Katz and Robert BeechChapter 6: The Long-term Natural History of Bipolar I DisorderZachary Engler and Robert BeechSection 3: Child and Adolescent DisordersChapter 7: The Multimodal Treatment Study of Children with Attention Deficit/Hyperactivity Disorder (MTA)Michael Hochman, edited by Michael H. BlochChapter 8: Adolescents with SSRI-Resistant Depression: The TORDIA TrialAmalia Londono Tobon and Hanna StevensChapter 9: Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) StudyJ. Corey Williams and Hanna StevensChapter 10: Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety: CAMSDavid Saunders, Jerome Taylor, and Andres MartinChapter 11: Predictors of Suicidal Events: The Treatment of Adolescent Suicide Attempters study (TASA)Michael Maksimowski and Zheala QayyumChapter 12: Cognitive Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents with OCDFalisha Gilman and Zheala QayyumChapter 13: Initial Treatment of Bipolar I Disorder in Children and Adolescents: The TEAM TrialStephanie Ng and Andres MartinChapter 14: The Treatment for Adolescents with Depression Study (TADS)Zachary Engler and Zheala QayyumSection 4: Cognitive Disorders: Delirium/DementiaChapter 15: Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease: CATIE-ADAdam Mecca and Rajesh R. TampiChapter 16: Risk of Death with Atypical Antipsychotic Medications for DementiaAdam Mecca and Rajesh R. TampiChapter 17: Treatment of Delirium in Hospitalized AIDS Patients: A Double-Blind Trial of Haloperidol, Chlorpromazine, and LorazepamAmanda Sun and Rajesh R. TampiChapter 18: Memantine in Patients with Moderate to Severe Alzheimer Disease Already Receiving DonepezilBrandon M. Kitay and Rajesh R. TampiSection 5: EpidemiologyChapter 19: Global Burden of Mental and Substance Use DisordersStephanie Yarnell and Ellen EdensChapter 20: Prevalence and Severity of Psychiatric Comorbidities: The National Comorbidity Survey Replication (NCS-R)Stephanie Yarnell and Ellen EdensSection 6: InsomniaChapter 21: Behavioral and/or Pharmacotherapy for Older Patients with InsomniaRobert Ross and Rajesh R. TampiSection 7: Major Depressive DisorderChapter 22: Treatment of Depression in Patients with Alcohol or Drug Dependence: A Meta-AnalysisJ. Corey Williams and Gustavo Angarita-AfricanoChapter 23: Suicidality in Pediatric Patients Treated with Antidepressant Drugs: FDA Meta-analysisDavid Saunders and Michael H. BlochChapter 24: National Institute of Mental Health (NIMH) Treatment of Depression Collaborative Research ProgramJoseph Taylor and Robert OstroffChapter 25: Efficacy and Safety of Electroconvulsive Therapy in Depressive Disorders: A Systematic Review and Meta-analysisJoseph Taylor and Robert OstroffChapter 26: Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug AdministrationMichael Maksimowski and Zheala QayyumChapter 27: Sequenced Treatment Alternatives to Relieve Depression: STAR*DEric Lin and Pochu HoChapter 28: Cognitive Therapy vs. Medication in the Treatment of Moderate to Severe DepressionDaniel Barron and Robert OstroffSection 8: Obsessive Compulsive DisorderChapter 29: Exposure and Ritual Prevention, Clomipramine, or Their Combination for Obsessive-Compulsive DisorderBrandon M. Kitay and Michael H. BlochChapter 30: Meta-analysis of the Dose-response relationship of SSRI's in adult patients with Obsessive Compulsive DisorderEunice Yuen and Michael H. BlochSection 9: Personality DisordersChapter 31: Psychotherapy for Borderline Personality Disorder: A Multiwave StudyDavid Grunwald, Erica Robinson, and Sarah FinebergChapter 32: Dialectical Behavior Therapy vs. Community Treatment by Experts for Reducing Suicidal Behaviors Among Patients with Borderline Personality DisorderDavid Saunders, Erica Robinson, and Sarah FinebergChapter 33: Ten-Year Course of Borderline Personality Disorder: The Collaborative Longitudinal Personality Disorders StudyKevin Johnson, Erica Robinson, and Sarah FinebergSection 10: Psychiatry in Primary CareChapter 34: Depressive Symptoms and Health-Related Quality of Life: The Heart and Soul StudyAmalia Londono Tobon and Catherine ChilesChapter 35: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) TrialNikhil Gupta and Catherine ChilesSection 11: Women's Mental HealthChapter 36: Buprenorphine vs. Methadone During Pregnancy: The MOTHER TrialRachel Wurmser and Kirstin WilkinsSection 12: SchizophreniaChapter 37: QTc-Interval Abnormalities and Psychotropic Drug Therapy in Psychiatric PatientsAmanda Sun and Vinod H. SrihariChapter 38: Tardive Dyskinesia with Atypical vs. Conventional Antipsychotic MedicationsEmma Lo and Cenk TekChapter 39: Effectiveness of Antipsychotics in the Treatment of Schizophrenia: CATIE Phase 1Chadrick Lane and Mohini RanganathanChapter 40: Clozapine for Treatment-Resistant SchizophreniaChadrick Lane and Vinod H. SrihariChapter 41: Effectiveness of clozapine vs. other atypical antipsychotics: Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE)Eunice Yuen and Cenk TekChapter 42: Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac DeathHamilton Hicks and Cenk TekChapter 43: Switching Antipsychotics to Reduce Metabolic Risk: The CAMP TrialEric Lin and John CahillChapter 44: Cost Utility of Atypical Antipsychotics: CUtLASS-1Nikhil Gupta and John CahillChapter 45: North American Prodrome Longitudinal StudyNikhil Gupta and Vinod H. SrihariChapter 46: Clozapine for Suicidality in Schizophrenia: The International Suicide Prevention Trial (InterSePT)Daniel Barron and Noah CapursoChapter 47: A Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for SchizophreniaStephanie Ng and Cenk TekSection 13: Substance Use DisordersChapter 48: Methadone Maintenance vs. Detoxification and Psychosocial Treatment for Opioid Dependence: The M180 StudyHamilton Hicks and Srinivas MuvvalaChapter 49: Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE StudyKevin Johnson and Srinivas MuvvalaChapter 50: Levomethadyl acetate vs. Buprenorphine vs. Methadone for Opioid DependenceRobert Ross and Brian Fuehrlein
